tbuckley/cabot-search huggingface dataset:
Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis
Authors: Stephen F. Stewart, Julian B. Leathart, Yuanneng Chen, Ann K. Daly, Roberta Rolla, Daria Vay, Elisa Mottaran, Matteo Vidali, Emanuele Albano, Chris P. Day
Journal: Hepatology (2002)

The role of genetic factors in the pathogenesis of alcohol-induced liver disease (ALD) is receiving increasing attention. Recently, it has been reported that homozygosity for a valine to alanine substitution in the mitochondrial targeting sequence of manganese superoxide dismutase (Mn-SOD) represents a risk factor for severe ALD. Because this mutation is postulated to modify enzyme transport into mitochondria, we have sought confirmatory evidence of this association in a larger group of patients and investigated whether this polymorphism might influence alcohol-induced oxidative stress. Genotyping for the valinealanine (Val-Ala) polymorphism of the Mn-SOD gene in 281 patients with advanced ALD (cirrhosis/fibrosis) and 218 drinkers without liver disease showed no differences in either the heterozygote (55% vs. 50%) or the homozygote (19% vs. 23%) frequency for the alanine allele. By measuring the titers of circulating antibodies against oxidized cardiolipin (OX-CL) and malondialdehyde (MDA) or hydroxy-ethyl radical (HER) adducts as markers of oxidative stress, we found a significant increase in ALD patients compared with healthy controls. However, the carriers of the alanine Mn-SOD allele had titers of anti-MDA, anti-HER, and anti-OX-CL IgG comparable with heterozygotes and patients homozygous for the valine allele. Similarly, the frequency of subjects with antibody titers above the 95th percentile of controls was not increased among homozygotes for the alanine Mn-SOD allele. In conclusion, in our population Val-Ala polymorphism in Mn-SOD influences neither susceptibility to alcohol-induced liver fibrosis nor alcohol-induced oxidative stress. (Hepatology2002;36:1355-1360).
TCT CONNECT-394 Incidence and Outcomes of Quantitative Flow Ratio−Based Optimal Revascularization in an All-Comers Study
Authors: Rui Zhang, Changdong Guan, Tongqiang Zou, Min Zhang, Zheng Qiao, Sheng Yuan, Lihua Xie, Zhongwei Sun, Lei Song, Kefei Dou, Gregg Stone, Bo Xu
Journal: Journal of the American College of Cardiology (2020)
Betulinic acid is an effective CD97 inhibitor in the human medullary thyroid carcinoma cell line MTC-SK
Authors: T. Mustafa, O. Gimm, Z. Chen, B. Trojanowicz, M. Erhuma, R. Zschoyan, A. Kehlen, H. Dralle, C. Hoang-Vu
Journal: Cancer Research (2004)

4238  Introduction: The heterodimeric CD97 protein is a member of the EGF-TM7 family of class II seven-transmembrane (7TM) receptors of 75-90 kD and structurally related to the secretin receptor family. CD97 is expressed on leucocytes, lymphocytes and in cells of the hematopoietic system and serves as a dedifferentiation marker in thyroid carcinogenesis. Due to the interaction with its ligand CD55, CD97 is involved in carcinoma cell spread and metastasis. Aim and Objectives: We investigated the regulation of CD97 under stimulation with 1μM all-trans-retinoic acid (RA), 3mM sodium butyrate (SB) and 2mM betulinic acid (BA) in the human MTC cell line MTC-SK by FACS analysis and real time PCR. The CD97 transcript of the unstimulated control was set to 100%. Results: The CD97 mRNA and protein expression remained still constant after 24h with and without RA, SB and BA. A significant decrease of CD97 mRNA/ protein expression was observed after 48 hours and continued after 72 hours. We observed a stronger downregulation of CD97 after BA treatment (48%) than under the influence of RA or SB ( both
Clinical size is a poor predictor of invasion in melanoma of the lentigo maligna type
Authors: Cristian Navarrete-Dechent, Saud Aleissa, Karen Connolly, Brian P. Hibler, Stephen W. Dusza, Anthony M. Rossi, Erica Lee, Kishwer S. Nehal
Journal: Journal of the American Academy of Dermatology (2020)
エタノールによる心筋細胞T型Ca 2+ チャネル発現調節は転写因子Csx/Nkx2.5及びGATA4に依存する
Authors: 王岩, 森島真幸, 嶋岡徹, 李泰成, 鄭明奇, 小野克重
Journal: Circulation (2007)
Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care
Authors: Raina M. Merchant, Alexis A. Topjian, Ashish R. Panchal, Adam Cheng, Khalid Aziz, Katherine M. Berg, Eric J. Lavonas, David J. Magid
Journal: Circulation (2020)

resuscitation ◼ defibrillators ◼ delivery of health care ◼ echocardiography ◼ electric countershock ◼ epinephrine ◼ extracorporeal membrane oxygenation ◼ heart arrest ◼ infusions, intraosseous ◼ intubation, intratracheal
TCT CONNECT-210 Three-Dimensional QCA-Based Vessel Fractional Flow Reserve (vFFR) in Heart Team Decision-Making: A Multicenter, Reclassification Study
Authors: Mariusz Tomaniak, Kaneshka Masdjedi, Tara Neleman, Ibrahim Kucuk, Alise Vermaire, Laurens Zandvoort, Bas van Dalen, Loe Kie Soei, Wijnand Den Dekker, Isabella Kardys, Roberto Diletti, Felix Zijlstra, Nicolas Van Mieghem, Joost Daemen
Journal: Journal of the American College of Cardiology (2020)
OP0138 Relative gastrointestinal toxicity of cox-2 specific and traditional nsaids in a high-risk population from a health maintenance organisation
Authors: D Pettitt, JL Goldstein, G Singh, JS Schwartz, TA Burke
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> COX-2 specific inhibitors (COX-2) are potentially prescribed to individuals at higher risk for adverse gastrointestinal (GI) outcomes, which produces "channelling" bias in nonrandomized observational studies. This bias may be minimised if the units of observation are the multiple drug exposure periods within high risk patients (ie individuals may be have both NSAID and COX-2 exposure periods). <h3>Objectives</h3> To quantify the relative risk reduction of GI events associated with the use of COX-2 and traditional NSAIDs in a high risk cohort. <h3>Methods</h3> All patients prescribed at least one COX-2 (celecoxib, rofecoxib) between 1/1–05/31/00 were identified from a ~3,000,000 member health maintenance organisation. Using physician recorded primary diagnoses, the following endpoints were examined: nonhospitalized GI discomfort (abdominal pain, nausea, dyspepsia, ulcer diagnosis without endoscopy) ± gastroprotective agent (GPA); and hospitalised or outpatient (with endoscopy) diagnosis of perforation, ulceration, or bleed (PUB). A multivariate Poisson regression model adjusting for the duration of drug exposure was used to compare the incidence of GI events associated with COX-2 or NSAID therapies (&gt;200 years exposure). The analysis adjusted for traditional GI risk factors (age, gender, arthritis diagnosis, comorid disease, GI history, drug dosing, concomitant GPA therapy, history of cardiovascular disease, corticosteroid therapy). <h3>Results</h3> The cohort consisted of 22,696 patients who received a total of 2,853 and 6,519 years of NSAID and COX-2 exposure, respectively. The patient demographics were: 33.8% male; 47% osteoarthritis; 12.4% rheumatoid arthritis; 28% GI history; 25% history of gastroprotective agent use; and 63.3 years of age. After adjusting for significant risk factors (α = 0.05), the relative risk reductions associated with COX-2 (bold) or NSAID therapy, using ibuprofen therapy as the standard, were as follows: <h3>Conclusion</h3> Consistent with clinical trial results, improved GI tolerability and safety is associated with the utilisation of COX-2 therapy compared to NSAIDs.
TCT CONNECT-91 Invasive Versus Echocardiographic Gradients Post Valve-in-Valve TAVR: A Multicenter Trial
Authors: Ramy Mando, Sammy Elmariah, George Hanzel, Alexander Camacho, Alexandra Selberg, Karim Al-Azizi, Amer N. Kadri, Jared Christensen, Molly Szerlip, Steven Almany, Alessandro Vivacqua, Michael Mack, Ivan Hanson, Francis Shannon, Amr Abbas
Journal: Journal of the American College of Cardiology (2020)
Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer
Authors: Di Maria Jiang, Nazanin Fallah-Rad, Roy Lee, Pamela Ng, Alan D. Smith, Aaron R. Hansen, Anthony M. Joshua, Jaclyn Beca, Srikala S. Sridhar
Journal: European Urology (2020)
TCT CONNECT-171 Compatibility of Novel Cardiogenic Shock Phenotypes From the Cardiogenic Shock Working Group (CSWG) With the SCAI Staging System
Authors: Elric Zweck, Manreet Kanwar, Katherine Thayer, Gavin Hickey, Arthur Garan, Jaime Hernandez Montfort, Song Li, Claudius Mahr, Daniel Burkhoff, Navin Kapur
Journal: Journal of the American College of Cardiology (2020)
Mitigating a COVID-19 Outbreak Among Major League Baseball Players — United States, 2020
Authors: Meghan T. Murray, Margaret A. Riggs, David M. Engelthaler, Caroline Johnson, Sharon Watkins, Allison Longenberger, David M. Brett-Major, John Lowe, M. Jana Broadhurst, Chandresh N. Ladva, Julie M. Villanueva, Adam MacNeil, Shoukat Qari, Hannah L. Kirking, Michael Cherry, Ali S. Khan
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Mass gatherings have been implicated in higher rates of transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), and many sporting events have been restricted or canceled to limit disease spread (1). Based on current CDC COVID-19 mitigation recommendations related to events and gatherings (2), Major League Baseball (MLB) developed new health and safety protocols before the July 24 start of the 2020 season. In addition, MLB made the decision that games would be played without spectators. Before a three-game series between teams A and B, the Philadelphia Department of Public Health was notified of a team A player with laboratory-confirmed COVID-19; the player was isolated as recommended (2). During the series and the week after, laboratory-confirmed COVID-19 was diagnosed among 19 additional team A players and staff members and one team B staff member. Throughout their potentially infectious periods, some asymptomatic team A players and coaches, who subsequently received positive SARS-CoV-2 test results, engaged in on-field play with teams B and C. No on-field team B or team C players or staff members subsequently received a clinical diagnosis of COVID-19. Certain MLB health and safety protocols, which include frequent diagnostic testing for rapid case identification, isolation of persons with positive test results, quarantine for close contacts, mask wearing, and social distancing, might have limited COVID-19 transmission between teams.
Abstract 15021: Resting Pulse Rate at Time of Diagnosis is Positively Associated With Mortality and Hospitalizations in a Large U.S. Cohort of Patients With Heart Failure With Reduced Ejection Fraction
Authors: Petra Schubert, Katherine Kurgansky, Rachel Parker, Luc Djousse, David Gagnon, Marc J Kozinn, Jacob Joseph
Journal: Circulation (2018)

Introduction: Limited studies in patients with heart failure with reduced ejection fraction (HFrEF) have examined the association between elevated pulse rate and increased mortality and hospitaliza...
TCT CONNECT-30 The Myocardial Contraction Fraction, A Volumetric Measure of Myocardial Shortening, Predicts Adverse Events After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: An Individual Patient-Level Data Analysis From 7 Randomized Trials
Authors: Mahesh Madhavan, Shmuel Chen, Bjorn Redfors, Bahira Shahim, Fotis Gkargkoulas, Manesh Patel, Zixuan Zhang, Ingo Eitel, Mathew Maurer, Holger Thiele, Gregg Stone
Journal: Journal of the American College of Cardiology (2020)
Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma
Authors: Nicole M Brossier, Sharanya Thondapu, Olivia M Cobb, Sonika Dahiya, David H Gutmann
Journal: Neuro-Oncology (2020)

Brain tumors are the most common solid tumors of childhood, but little is understood about the factors that influence their development. Pediatric low-grade gliomas in particular display unique temporal and spatial localization associated with different genetic mutations (eg, BRAF genomic alterations, mutations in the neurofibromatosis type 1 [NF1] gene) for reasons that remain unclear. NF1 low-grade gliomas typically arise in the optic pathway of young children as optic pathway gliomas (OPGs), likely from a cell of origin that resides within the third ventricular zone (TVZ). However, the factors that contribute to their distinct temporal patterning and penetrance have not been adequately explored.TVZ neuroglial progenitor cells (NPCs) were analyzed over the course of mouse brain development. Progenitors isolated by fluorescence-activated cell sorting (FACS) were assessed for functional and molecular differences. The impact of different germline Nf1 mutations on TVZ NPC properties was analyzed using genetically engineered mice.We identify 3 individual factors that could each contribute to Nf1 optic glioma temporal patterning and penetrance. First, there are 3 functionally and molecularly distinct populations of mouse TVZ NPCs, one of which ("M" cells) exhibits the highest clonogenic incidence, proliferation, and abundance during embryogenesis. Second, TVZ NPC proliferation dramatically decreases after birth. Third, germline Nf1 mutations differentially increase TVZ NPC proliferation during embryogenesis.The unique temporal patterning and penetrance of Nf1 optic glioma reflects the combined effects of TVZ NPC population composition, time-dependent changes in progenitor proliferation, and the differential impact of the germline Nf1 mutation on TVZ NPC expansion.
TCT CONNECT-320 Unmasking Syndrome X by Angiographic and Artificial Intelligence Programs
Authors: Thach Nguyen, Tra Ngo, Dung Ho Thuong, Hoang Nguyen, Phuoc Nguyen, Wai Yan Thein, Duy Chung, Luan Ngo, Phuong Nguyen, Loc Vu, Duy Nguyen, Nga Nguyen, Thai Truong, Robert Luscomb, Luan Nguyen, Nhi Trinh, Nhan Tran, Lanh Nguyen, Thao Nguyen, Duc Truong, Loi Phan, Hien Duong, Nha Chau, Gianluca Rigatelli, Ernest Talarico, Thinh Cao, Hung Pham
Journal: Journal of the American College of Cardiology (2020)
The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study
Authors: Hans Ackerman, Aintzane Ayestaran, Christopher H O Olola, Muminatou Jallow, Tsiri Agbenyega, Kalifa Bojang, David J Roberts, Sanjeev Krishna, Peter G Kremsner, Charles R Newton, Terrie Taylor, Clarissa Valim, Climent Casals-Pascual
Journal: The Lancet Haematology (2020)
TCT CONNECT-418 Evaluation of Nerve Injury and Regrowth Following Renal Denervation in Swine Model
Authors: Andrew Sharp, Stefan Tunev, Markus Schlaich, David Lee, Aloke Finn, Felix Mahfoud, Robert Melder, Julie Trudel, Paul Coates, David Kandzari
Journal: Journal of the American College of Cardiology (2020)
Interaction between high-density lipoproteins and inflammation: Function matters more than concentration!
Authors: Sumra Nazir, Vera Jankowski, Guzide Bender, Stephen Zewinger, Kerry-Anne Rye, Emiel P.C. van der Vorst
Journal: Advanced Drug Delivery Reviews (2020)

High-density lipoprotein (HDL) plays an important role in lipid metabolism and especially contributes to the reverse cholesterol transport pathway. Over recent years it has become clear that the effect of HDL on immune-modulation is not only dependent on HDL concentration but also and perhaps even more so on HDL function. This review will provide a concise general introduction to HDL followed by an overview of post-translational modifications of HDL and a detailed overview of the role of HDL in inflammatory diseases. The clinical potential of HDL and its main apolipoprotein constituent, apoA-I, is also addressed in this context. Finally, some conclusions and remarks that are important for future HDL-based research and further development of HDL-focused therapies are discussed.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
Authors: Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang, Quanren Wang
Journal: Clinical Cancer Research (2020)

We assessed the efficacy and safety of camrelizumab [an anti-programmed death (PD-1) mAb] plus apatinib (a VEGFR-2 tyrosine kinase inhibitor) in patients with advanced hepatocellular carcinoma (HCC).This nonrandomized, open-label, multicenter, phase II study enrolled patients with advanced HCC who were treatment-naïve or refractory/intolerant to first-line targeted therapy. Patients received intravenous camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily. The primary endpoint was objective response rate (ORR) assessed by an independent review committee (IRC) per RECIST v1.1.Seventy patients in the first-line setting and 120 patients in the second-line setting were enrolled. As of January 10, 2020, the ORR was 34.3% [24/70; 95% confidence interval (CI), 23.3-46.6] in the first-line and 22.5% (27/120; 95% CI, 15.4-31.0) in the second-line cohort per IRC. Median progression-free survival in both cohorts was 5.7 months (95% CI, 5.4-7.4) and 5.5 months (95% CI, 3.7-5.6), respectively. The 12-month survival rate was 74.7% (95% CI, 62.5-83.5) and 68.2% (95% CI, 59.0-75.7), respectively. Grade ≥3 treatment-related adverse events (TRAE) were reported in 147 (77.4%) of 190 patients, with the most common being hypertension (34.2%). Serious TRAEs occurred in 55 (28.9%) patients. Two (1.1%) treatment-related deaths occurred.Camrelizumab combined with apatinib showed promising efficacy and manageable safety in patients with advanced HCC in both the first-line and second-line setting. It might represent a novel treatment option for these patients.See related commentary by Pinato et al., p. 908.
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection
Authors: Kathrin Heim, Benedikt Binder, None Sagar, Dominik Wieland, Nina Hensel, Sian Llewellyn-Lacey, Emma Gostick, David A. Price, Florian Emmerich, Hildegard Vingerhoet, Anke R M Kraft, Markus Cornberg, Tobias Boettler, Christoph Neumann-Haefelin, Dietmar Zehn, Bertram Bengsch, Maike Hofmann, Robert Thimme
Journal: Gut (2020)

Objective Chronic hepatitis B virus (HBV) infection is characterised by HBV-specific CD8+ T cell dysfunction that has been linked to Tcell exhaustion, a distinct differentiation programme associated with persisting antigen recognition. Recently, Thymocyte Selection-Associated High Mobility Group Box (TOX) was identified as master regulator of CD8+ T cell exhaustion. Here, we addressed the role of TOX in HBV-specific CD8+ T cell dysfunction associated with different clinical phases of infection. Design We investigated TOX expression in HBV-specific CD8+ T cells from 53 HLA-A*01:01, HLA-A*11:01 and HLA-A*02:01 positive patients from different HBV infection phases and compared it to hepatitis C virus (HCV)-specific, cytomegalovirus (CMV)-specific, Epstein-Barr virus (EBV)-specific and influenza virus (FLU)-specific CD8+ T cells. Phenotypic and functional analyses of virus-specific CD8+ T cells were performed after peptide-loaded tetramer-enrichment and peptide-specific expansion. Results Our results show that TOX expression in HBV-specific CD8+ T cells is linked to chronic antigen stimulation, correlates with viral load and is associated with phenotypic and functional characteristics of T-cell exhaustion. In contrast, similar TOX expression in EBV-specific and CMV-specific CD8+ T cells is not linked to T-cell dysfunction suggesting different underlying programmes. TOX expression in HBV-specific CD8+ T cells is also affected by targeted antigens, for example, core versus polymerase. In HBV-specific CD8+ T cells, TOX expression is maintained after spontaneous or therapy-mediated viral control in chronic but not self-limiting acute HBV infection indicating a permanent molecular imprint after chronic but not temporary stimulation. Conclusion Our data highlight TOX as biomarker specific for dysfunctional virus-specific CD8+ T cells in the context of an actively persisting infection.
Protein-C concentrate for meningococcal purpura fulminans (multiple letters) [3]
Authors: W. Kreuz, A. Veldman, C. Escuriola-Ettingshausen, W. Schneider, T. Beeg, R. Charlton, G. S. Arul, L. Sacks, A. Wolf, M. Gargan, D. Spicer
Journal: The Lancet (1998)
Scientific petitions and open letters in the era of covid-19
Authors: John PA Ioannidis
Journal: BMJ (2020)

Petitions and open letters signed by large numbers of scientists are not new, but they have proliferated in the covid-19 era. 1 2 They have a clear role when it comes to questions of ethics, social problems, and injustices.With monumental consequences from both the pandemic and the response to the pandemic, debating ethical and social matters is the right of every citizen, including scientists.A collateral damage, however, is when these documents are aimed to prove or disprove scientific positions.
A Hyper-IgM Syndrome Mutation in Activation-Induced Cytidine Deaminase Disrupts G-Quadruplex Binding and Genome-wide Chromatin Localization
Authors: William T. Yewdell, Youngjun Kim, Priyanka Chowdhury, Colleen M. Lau, Ryan M. Smolkin, Kalina T. Belcheva, Keith C. Fernandez, Montserrat Cols, Wei-Feng Yen, Bharat Vaidyanathan, Davide Angeletti, Adrian B. McDermott, Jonathan W. Yewdell, Joseph C. Sun, Jayanta Chaudhuri
Journal: Immunity (2020)
Assessment of the American College of Surgeons surgical risk calculator of outcomes after hepatectomy for liver tumors: Results from a cohort of 950 patients
Authors: Matteo Donadon, Jacopo Galvanin, Bruno Branciforte, Angela Palmisano, Fabio Procopio, Matteo Cimino, Daniele Del Fabbro, Guido Torzilli
Journal: International Journal of Surgery (2020)
Basophil activation and serum IL‐5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with anti‐IL‐5 drugs
Authors: Cristiano Caruso, Stefania Colantuono, Barbara Tolusso, Clara Di Mario, Antonella Pentassuglia, Gabriele Rumi, Elisa Gremese, Antonino Romano, Antonio Gasbarrini
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
TCT CONNECT-270 FANTOM II Trial: Safety and Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold—First Report: 4-Year Clinical Outcomes
Authors: Matthias Lutz, Jeffrey Anderson, Alexandre Abizaid, Didier Carrie, Norbert Frey, Bernard Chevalier
Journal: Journal of the American College of Cardiology (2020)
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH
Authors: Akhila Kavirayani, James E G Charlesworth, Shelley Segal, Dominic Kelly, Shaun Wilson, Amrana Qureshi, Esther Blanco, James Weitz, Deirdre O'Shea, Kathryn Bailey
Journal: The Lancet Rheumatology (2020)
TCT CONNECT-469 Paravalvular Aortic Regurgitation After TAVI. Aortography, Echocardiography and Hemodynamic Assessment in Relation to Survival
Authors: Gabor Dekany, Zsolt Gabor Piroth, Geza Fontos, Tunde Pinter, Marton Vertesaljai, Matyas Pal, Sai Satish, Tamas Fereci, Adrienn Mandzak, Gergely Szabo, Zalán Gulyás, Peter Andreka
Journal: Journal of the American College of Cardiology (2020)
Reply to: Medical algorithm: Diagnosis and treatment of preschool asthma
Authors: Tuomas Jartti, Nikolaos G. Papadopoulos, Wojciech Feleszko
Journal: Allergy (2020)

Dr Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work.